Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Select Medical Holdings (SEM) Other financing activities (2018 - 2025)

Select Medical Holdings (SEM) has disclosed Other financing activities for 7 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Other financing activities fell 53.33% to $2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.9 million, a 1.22% increase, with the full-year FY2025 number at $15.9 million, up 1.22% from a year prior.
  • Other financing activities was $2.9 million for Q4 2025 at Select Medical Holdings, up from $2.1 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $14.2 million in Q3 2021 to a low of $141000.0 in Q3 2022.
  • A 5-year average of $4.5 million and a median of $3.0 million in 2025 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: skyrocketed 81157.14% in 2021, then plummeted 99.01% in 2022.
  • Select Medical Holdings' Other financing activities stood at $806000.0 in 2021, then soared by 201.99% to $2.4 million in 2022, then grew by 1.56% to $2.5 million in 2023, then soared by 154.85% to $6.3 million in 2024, then plummeted by 53.33% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for SEM's Other financing activities are $2.9 million (Q4 2025), $2.1 million (Q3 2025), and $3.0 million (Q2 2025).